COPD (With - Without Rehabilitation), Cystic Fibrosis of the Adult, Diffuse Interstitial Lung Diseases, Pulmonary Arterial Hypertension Primary or Secondary (Post Embolic .....)
Conditions
Keywords
Dyspnea, Self-administered questionnaire, Chronic respiratory disease, COPD, Diffuse interstitial lung diseases, Pulmonary arterial hypertension, Cystic fibrosis
Brief summary
The purpose of this study is the psychometric validation of a self-administered dyspnea questionnaire, usable in clinical practice in order to assess dyspnea and its impact on patients with chronic respiratory diseases.
Detailed description
Dyspnea is a cardinal Respiratory symptom. According to the ATS dyspnea is the term used to characterize a subjective experience of breathing discomfort, covering qualitatively distinct sensations of varying intensity. The subjective nature of dyspnea and the high complexity of its determinants explain the often moderate correlations obtained with physiological data. Dyspnea must therefore be measured specifically. The aim of this study is the cross-sectional and longitudinal psychometric validation of a self-administered dyspnea questionnaire (assessing the impact of dyspnea on activities restriction), usable in clinical practice in order to assess dyspnea and its alterations in adult patients with chronic respiratory diseases. (COPD, diffuse interstitial lung diseases, Pulmonary arterial hypertension, Cystic fibrosis) Like any psychometric instrument, an efficient evaluation of dyspnea scale should ideally satisfy all the following required features: evaluative, discriminant, good reproducibility, and high sensitivity to change. The desired features apart from content validity are reproducibility and especially a high sensitivity to change, particularly following pulmonary rehabilitation. Thus, this questionnaire should precisely enable to assess the benefit of rehabilitation and it's sustainment in maintenance phase.
Interventions
OTHERCross sectional psychometric evaluation of a self-administered dyspnea questionnaire.
Evaluation will be performed on a group of 200 patients deriving from 4 samples. * From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD). * From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment.
Sponsors
Pr Joel COSTE, Hôpital Hôtel Dieu - Unité de Bio Statistiques et Epidémiologiques, Paris
URC-CIC Paris Descartes Necker Cochin
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\) Sample1: COPD GOLD / ATS \> 2 without major co-morbidity * Sample 1A: n = 50: group of patients with no change in usual care and no acute event (evaluation of reproducibility) * Sample1B: n = 60: patients assessed before and after a qualifying period of pulmonary rehabilitation * 2\) Sample 2 (n = 30): diffuse interstitial lung diseases Criteria: Pulmonary Fibrosis: Idiopathic or nonspecific interstitial lung diseases (NILD) according to international criteria (ATS), sarcoidosis with parenchymal lesions (old classification stage II and III), and exceptionally alveolar proteinosis. * 3\) Sample 3 (n = 30) primary or secondary arterial pulmonary hypertension (post embolic .....). * 4\) Sample4 (n = 30): Adult with Cystic fibrosis. * 5\) patient with stable Status (no exacerbation for at least one month)
Exclusion criteria
* 1\) Patient under 18 years * 2\) Inability to fill in questionnaires * 3\) Other respiratory disease * 4\) left symptomatic heart failure * 5\) Obesity with a BMI\> 35 kg/m2 * 6\) Inability to perform PFT (Pulmonary Function Testing) * 7\) Pregnant or breastfeeding woman * 8\) Patient unable to consent * 9\) Lack of social insurance coverage * 10\) Patient in exclusion period because of another protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Psychometric validity of the questionnaire | Until end of treatment (making a total of 6 months) | Cross-sectional and longitudinal psychometric validation of a self-administered dyspnea questionnaire |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Structural analysis (in principal components) | Until end of treatment (making a total of 6 months) | Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire |
| External and convergent validity | Until end of treatment (making a total of 6 months) | Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire |
| Internal coherence | Until end of treatment (making a total of 6 months) | Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire |
| Reproducibility | Until end of treatment (making a total of 6 months) | Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire |
| Analysis of responses distribution | Until end of treatment (making a total of 6 months) | Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire |
| Derivation of a scoring algorithm | Until end of treatment (making a total of 6 months) | Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire |
| Sensitivity to change | Until end of treatment (making a total of 6 months) | Sensitivity to change will be analyzed in relation to: The TDI score, at the Likert scale on changes in dyspnea The scores of quality of life with their respective significant thresholds A the overall medical evaluation A changing EFR parameters with their respective significant thresholds (FEV, DLCO, walk test .....). All this are the transversal data necessaries to assess the validation of a psychometric self-administered dyspnea questionnaire. |
| Minimal difference clinically relevant | Until end of treatment (making a total of 6 months) | Cross-sectional data necessary to assess the psychometric validity of a self-administered dyspnea questionnaire |
| Discriminating properties | Until end of treatment (making a total of 6 months) | Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire |
Countries
France
Outcome results
None listed